Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
With a market cap of 242.77B, Merck(MRK) trades at $98.13. The stock has a price-to-earnings ratio of 12.93 and currently yields dividends of 3.3%.
As of 2025-11-22, Merck(MRK) stock has fluctuated between $95.08 and $100.27. The current price stands at $98.13, placing the stock +3.2% above today's low and -2.1% off the high.
The Merck(MRK)'s current trading volume is 23.18M, compared to an average daily volume of 16.56M.
During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.
During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.
MRK News
Schwab US Dividend Equity ETF ( $SCHD ) has risen by 0.37% in the past week. It has experienced a 5-day net outflow of $54.69 million. This is due, in part, to...
(RTTNews) - Merck & Co Inc. (MRK) has been notified that Tutanota LLC has commenced an unsolicited mini-tender offer, dated November 10, 2025, to purchase up to...
Merck (MRK) has been notified that Tutanota LLC has commenced an unsolicited “mini-tender” offer, dated November 10, 2025, to purchase up to 1,000,000 shares of...
Analyst ratings
59%
of 29 ratingsMore MRK News
Shares of Merck & Company, Inc. (NASDAQ:MRK) are trading higher the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer....
The pharmaceutical giant's post-Keytruda plans continue to take shape. Over the past two years, Merck (MRK +0.06%) has faced several challenges, resulting in a...
Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen...
Merck (MRK) announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of d...
Merck (MRK) announced that the European Commission has approved a new subcutaneous, or under the skin, route of administration and a new pharmaceutical form of...
In November 2025, Merck announced a quarterly dividend increase and released positive clinical trial results for both WINREVAIR in pulmonary hypertension and en...
Merck & Co. Inc. (NYSE:MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and...
